BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Drobin K, Assadi G, Hong MG, Andersson E, Fredolini C, Forsström B, Reznichenko A, Akhter T, Ek WE, Bonfiglio F, Hansen MB, Sandberg K, Greco D, Repsilber D, Schwenk JM, D'Amato M, Halfvarson J. Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci. Inflamm Bowel Dis 2019;25:306-16. [PMID: 30358838 DOI: 10.1093/ibd/izy326] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Dovrolis N, Filidou E, Kolios G. Systems biology in inflammatory bowel diseases: on the way to precision medicine. Ann Gastroenterol 2019;32:233-46. [PMID: 31040620 DOI: 10.20524/aog.2019.0373] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Cui G, Fan Q, Li Z, Goll R, Florholmen J. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. EBioMedicine 2021;66:103329. [PMID: 33862588 DOI: 10.1016/j.ebiom.2021.103329] [Reference Citation Analysis]
3 Moret-Tatay I, Cerrillo E, Hervás D, Iborra M, Sáez-González E, Forment J, Tortosa L, Nos P, Gadea J, Beltrán B. Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications. Clin Transl Gastroenterol 2021;12:e00416. [PMID: 34695034 DOI: 10.14309/ctg.0000000000000416] [Reference Citation Analysis]
4 Brubaker DK, Kumar MP, Chiswick EL, Gregg C, Starchenko A, Vega PN, Southard-Smith AN, Simmons AJ, Scoville EA, Coburn LA, Wilson KT, Lau KS, Lauffenburger DA. An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease. Sci Signal 2020;13:eaay3258. [PMID: 32753478 DOI: 10.1126/scisignal.aay3258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Denson LA, Curran M, Mcgovern DPB, Koltun WA, Duerr RH, Kim SC, Sartor RB, Sylvester FA, Abraham C, de Zoeten EF, Siegel CA, Burns RM, Dobes AM, Shtraizent N, Honig G, Heller CA, Hurtado-lorenzo A, Cho JH. Challenges in IBD Research: Precision Medicine. Inflammatory Bowel Diseases 2019;25:S31-9. [DOI: 10.1093/ibd/izz078] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 15.3] [Reference Citation Analysis]
6 Chen P, Zhou G, Lin J, Li L, Zeng Z, Chen M, Zhang S. Serum Biomarkers for Inflammatory Bowel Disease. Front Med (Lausanne). 2020;7:123. [PMID: 32391365 DOI: 10.3389/fmed.2020.00123] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
7 Fart F, Salihović S, McGlinchey A, Gareau MG, Orešič M, Halfvarson J, Hyötyläinen T, Schoultz I. Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and induce intestinal barrier defects ex vivo in murine intestinal tissue. Scand J Gastroenterol 2021;:1-10. [PMID: 34383611 DOI: 10.1080/00365521.2021.1961306] [Reference Citation Analysis]
8 Edfors F, Iglesias MJ, Butler LM, Odeberg J. Proteomics in thrombosis research. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12706] [Reference Citation Analysis]